Prednisone, Lupus Activity, and Permanent Organ Damage

REFERENCES

1. 1.↵
   1. Goldblatt F,
   2. Isenberg DA

   . New therapies for systemic lupuserythematosus. Clin Exp Immunol 2005;140:205–12.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Karlson EW,
   2. Daltroy LH,
   3. Lew RA,
   4. et al

   . The relationship of socioeconomic status, race and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:47–56.

   OpenUrlPubMed
3. 3.↵
   1. Zonana-Nacach A,
   2. Barr SG,
   3. Magder LS,
   4. Petri M

   . Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801–8.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Gladman DD,
   2. Urowitz MB,
   3. Rahman P,
   4. Ibanez D,
   5. Tam LS

   . Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Toloza SM,
   2. Roseman JM,
   3. Alarcón GS,
   4. et al

   . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004;50:3177–86.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Nossent JC

   . LDICC/ACR damage index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy and prognosis. J Rheumatol 1998;25:654–9.

   OpenUrlPubMed
7. 7.↵
   1. Hernan MA,
   2. Hernandez-Diaz S,
   3. Robins JM

   . A structural approach to selection bias. Epidemiology 2004;15:615–25.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Hernan MA,
   2. Brumback B,
   3. Robins JM

   . Marginal structural models to estimate the joint effect of non randomized treatments. J Am Stat Assoc 2001;96:440–8.

   OpenUrlCrossRef
9. 9.↵
   1. Petri M

   . Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000;26:199–213.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Petri M

    . Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort. Lupus 2005;14:970–3.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Petri M,
    2. Barr SG,
    3. Zonana-Nach A,
    4. Magder L

    . Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. J Rheumatol 1999;26:502–3.

    OpenUrlPubMed
12. 12.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. et al

    . The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.

    OpenUrlPubMed
13. 13.↵
    1. Gladman DD,
    2. Urowitz MB,
    3. Goldsmith CH,
    4. et al

    . The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809–13.

    OpenUrlPubMed
14. 14.↵
    1. Bombardier C,
    2. Gladman DD,
    3. Urowitz MB,
    4. Caron D,
    5. Chang CH

    . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.

    OpenUrlPubMed
15. 15.↵
    1. Hernan MA,
    2. Hernandez-Diaz S,
    3. Robins JM

    . A structural approach to selection bias. Epidemiology 2004;15:615–25.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Robins JM,
    2. Hernan MA,
    3. Brumback B

    . Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550–60.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Hernan MA,
    2. Brumback B,
    3. Robins JM

    . Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 2000;11:561–70.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Hernan MA,
    2. Brumback B,
    3. Robins JM

    . Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 2002;21:1689–709.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Hernan MA,
    2. Brumback B,
    3. Robins JM

    . Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 2000;1:561–70.

    OpenUrl
20. 20.
    1. Choi HK,
    2. Hernán MA,
    3. Seeger JD,
    4. Robins JM,
    5. Wolfe F

    . Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173–7.

    OpenUrlCrossRefPubMed
21. 21.
    1. Cook NR,
    2. Cole SR,
    3. Hennekens CH

    . Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians’ Health Study. Am J Epidemiol 2002;155:1045–53.

    OpenUrlAbstract/FREE Full Text
22. 22.
    1. Hernan MA,
    2. Brumback BA,
    3. Robins JM

    . Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 2002;21:689–1709.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Cole SR,
    2. Hernan MA,
    3. Robins JM,
    4. et al

    . Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003;158:687–94.

    OpenUrlAbstract/FREE Full Text